Oncologic Significance of Therapeutic Delays in Patients With Oral Cavity Cancer.
Journal
JAMA otolaryngology-- head & neck surgery
ISSN: 2168-619X
Titre abrégé: JAMA Otolaryngol Head Neck Surg
Pays: United States
ID NLM: 101589542
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
pmc-release:
09
07
2024
medline:
10
11
2023
pubmed:
9
7
2023
entrez:
9
7
2023
Statut:
ppublish
Résumé
Oral cavity cancer often requires multidisciplinary management, subjecting patients to complex therapeutic trajectories. Prolonged treatment intervals in oral cavity cancer have been associated with poor oncological outcomes, but there has yet to be a study investigating treatment times in Canada. To report treatment delays for patients with oral cavity cancer in Canada and evaluate the outcomes of treatment delays on overall survival. This multicenter cohort study was performed at 8 Canadian academic centers from 2005 to 2019. Participants were patients with oral cavity cancer who underwent surgery and adjuvant radiation therapy. Analysis was performed in January 2023. Treatment intervals evaluated were surgery to initiation of postoperative radiation therapy interval (S-PORT) and radiation therapy interval (RTI). The exposure variables were prolonged intervals, respectively defined as index S-PORT greater than 42 days and RTI greater than 46 days. Patient demographics, Charlson Comorbidity Index, smoking status, alcohol status, and cancer staging were also considered. Univariate (log rank and Kaplan-Meier) and multivariate (Cox regression) analyses were performed to determine associations with overall survival (OS). Overall, 1368 patients were included; median (IQR) age at diagnosis was 61 (54-70) years, and 896 (65%) were men. Median (IQR) S-PORT was 56 (46-68) days, with 1093 (80%) patients waiting greater than 42 days, and median (IQR) RTI was 43 (41-47) days, with 353 (26%) patients having treatment time interval greater than 46 days. There were variations in treatment time intervals between institutions for S-PORT (institution with longest vs shortest median S-PORT, 64 days vs 48 days; η2 = 0.023) and RTI (institution with longest vs shortest median RTI, 44 days vs 40 days; η2 = 0.022). Median follow-up was 34 months. The 3-year OS was 68%. In univariate analysis, patients with prolonged S-PORT had worse survival at 3 years (66% vs 77%; odds ratio 1.75; 95% CI, 1.27-2.42), whereas prolonged RTI (67% vs 69%; odds ratio 1.06; 95% CI, 0.81-1.38) was not associated with OS. Other factors associated with OS were age, Charlson Comorbidity Index, alcohol status, T category, N category, and institution. In the multivariate model, prolonged S-PORT remained independently associated with OS (hazard ratio, 1.39; 95% CI, 1.07-1.80). In this multicenter cohort study of patients with oral cavity cancer requiring multimodal therapy, initiation of radiation therapy within 42 days from surgery was associated with improved survival. However, in Canada, only a minority completed S-PORT within the recommended time, whereas most had an appropriate RTI. An interinstitution variation existed in terms of treatment time intervals. Institutions should aim to identify reasons for delays in their respective centers, and efforts and resources should be directed toward achieving timely completion of S-PORT.
Identifiants
pubmed: 37422839
pii: 2807240
doi: 10.1001/jamaoto.2023.1936
pmc: PMC10331621
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
961-969Commentaires et corrections
Type : CommentIn
Références
Head Neck. 2016 Apr;38 Suppl 1:E1544-53
pubmed: 26890807
JCO Oncol Pract. 2021 Oct;17(10):e1512-e1523
pubmed: 33689399
JAMA Otolaryngol Head Neck Surg. 2020 Dec 1;146(12):1136-1146
pubmed: 33090191
Cancer. 2015 Apr 15;121(8):1204-13
pubmed: 25490875
Cancer. 2017 Jul 15;123(14):2651-2660
pubmed: 28241092
Cancer. 2017 Dec 15;123(24):4841-4850
pubmed: 28841234
Cancer. 2018 Aug 1;124(15):3154-3162
pubmed: 29742280
Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):967-975
pubmed: 27869097
JAMA Otolaryngol Head Neck Surg. 2023 Jan 1;149(1):63-70
pubmed: 36416855
Head Neck. 2020 Oct;42(10):2948-2957
pubmed: 33174308
Laryngoscope. 2017 Mar;127(3):616-622
pubmed: 27653749
JAMA Otolaryngol Head Neck Surg. 2019 Feb 1;145(2):166-177
pubmed: 30383146
Otolaryngol Head Neck Surg. 2018 Jul;159(1):158-165
pubmed: 29631478
Head Neck. 2017 Apr;39(4):639-646
pubmed: 28236349
Otolaryngol Head Neck Surg. 2018 Jun;158(6):1051-1056
pubmed: 29313448
BMJ. 2020 Nov 4;371:m4087
pubmed: 33148535
Cancer. 2017 Nov 15;123(22):4372-4381
pubmed: 28727137
JCO Oncol Pract. 2020 Dec;16(12):e1417-e1432
pubmed: 32853120
Eur J Cancer. 2017 Feb;72:226-234
pubmed: 28056426
J Clin Oncol. 2016 Jan 10;34(2):169-78
pubmed: 26628469
Eur J Surg Oncol. 2021 Jun;47(6):1398-1405
pubmed: 33648773
Br J Cancer. 2011 Apr 12;104(8):1246-8
pubmed: 21448166
Head Neck. 2021 Nov;43(11):3530-3539
pubmed: 34492135
J Natl Compr Canc Netw. 2020 Jul;18(7):873-898
pubmed: 32634781
Laryngoscope. 2018 Oct;128(10):2326-2332
pubmed: 29481712